In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing strategy.

They discuss why the US is no longer an isolated “free pricing” island, how UK and EU prices can now feed back into US revenues, and why small and mid‑size biotechs, in particular, can no longer afford to treat US and ex‑US strategies as separate worlds.

If you’re in pharma/biotech, pricing & market access or RWE, and you’re not yet stress‑testing your global evidence, price floors and launch plan against MFN and NICE reforms, this episode is your wake‑up call.

https://becarispublishing.com/doi/10.57264/cer-2026-0041

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #HealthPolicy #HealthcareFinance #HealthFinancing #HealthInvestment #NICEReform #IRAPricing #MFNPolicy #BiotechValueCreation #GlobalLaunchStrategy #marketaccesspodcast